Institute of Nutrition and Food Technology "José Mataix", Center of Biomedical Research, University of Granada, Avda. del Conocimiento s/n, 18016, Armilla, Granada, Spain.
Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, 20133, Milan, Italy.
Arch Biochem Biophys. 2021 Nov 15;712:109040. doi: 10.1016/j.abb.2021.109040. Epub 2021 Sep 20.
Epigenetic modifiers, such as methyltransferases, play crucial roles in the regulation of many biological processes, including development, cancer and multiple physiopathological conditions.
The Su(Var)3-9, Enhancer-of-zeste and Trithorax (SET) and Myeloid, Nervy, and DEAF-1 (MYND) domain-containing (SMYD) protein family consists of five members in humans and mice (i.e. SMYD1, SMYD2, SMYD3, SMYD4 and SMYD5), which are known or predicted to have methyltransferase activity on histone and non-histone substrates. The abundance of information concerning SMYD2 and SMYD3 is of note, whereas the other members of the SMYD family have not been so thoroughly studied CONCLUSION: Here we review the literature regarding SMYD proteins published in the last five years, including basic molecular biology mechanistic studies using in vitro systems and animal models, as well as human studies with a more translational or clinical approach.
表观遗传修饰物，如甲基转移酶，在许多生物学过程的调节中发挥着关键作用，包括发育、癌症和多种生理病理状况。
Su(Var)3-9、增强子-of-zeste 和 Trithorax（SET）和髓样、神经和 DEAF-1（MYND）结构域包含（SMYD）蛋白家族在人类和小鼠中由五个成员组成（即 SMYD1、SMYD2、SMYD3、SMYD4 和 SMYD5），它们已知或预测对组蛋白和非组蛋白底物具有甲基转移酶活性。值得注意的是，SMYD2 和 SMYD3 的信息量丰富，而 SMYD 家族的其他成员则没有得到如此彻底的研究。
在这里，我们回顾了过去五年中发表的关于 SMYD 蛋白的文献，包括使用体外系统和动物模型的基础分子生物学机制研究，以及更具转化或临床意义的人类研究。
